Arbutus Biopharma (ABUS) Restructuring Costs (2015 - 2025)

Arbutus Biopharma (ABUS) posted quarterly Restructuring Costs of $303000.0 for Q4 2025, up 218.95% year-on-year from $95000.0 in Q4 2024, and up 209.18% on a QoQ basis from $98000.0 in Q3 2025.

Arbutus Biopharma (ABUS) Restructuring Costs (2015 - 2025) Analysis & Trends

Arbutus Biopharma (ABUS) has reported Restructuring Costs for 6 consecutive years, with $303000.0 the latest figure, recorded in Q4 2025.

  • Quarterly Restructuring Costs rose 218.95% year-over-year to $303000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $12.8 million (down 20.46% YoY) and the FY2025 annual result came in at $12.9 million, up 247.82% from the prior year.
  • Restructuring Costs advanced to $303000.0 in Q4 2025 per ABUS's latest filing, from $98000.0 in the prior quarter.
  • Over the last five years, Restructuring Costs for ABUS reached as high as $12.4 million in Q2 2025 and fell as low as $95000.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Arbutus Biopharma 880.36 Mn 785.13 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 303,000.00
Sep 30, 2025 98,000.00
Jun 30, 2025 12.40 Mn
Mar 31, 2025 12.37 Mn
Dec 31, 2024 95,000.00
Sep 30, 2024 3.63 Mn
Jun 30, 2020 7,000.00
Mar 31, 2020 57,000.00
Dec 31, 2019 123,000.00
Sep 30, 2019 182,000.00
Jun 30, 2019 -266,000.00
Mar 31, 2019 4.90 Mn
Dec 31, 2018 1.09 Mn
Sep 30, 2018 -492,000.00
Jun 30, 2018 2.58 Mn
Mar 31, 2018 1.62 Mn
Jun 30, 2015 361,000.00
Mar 31, 2015 9.30 Mn